SEARCH RESULT

Total Matching Records found : 39

Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan

-The Times of India NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease. The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction...

More »

Questions about India’s drug industry-Narayan Lakshman

-The Hindu Unless a deeper, institutional change is ushered in to break the nexus between drug companies and the regulatory regime, Indians consuming drugs may be exposing themselves to serious risks Even before I walked into the Mayflower Hotel in the heart of Washington on a crisp autumn afternoon to meet Dinesh Thakur, whistle-blower and former director of India-based pharmaceutical giant Ranbaxy, I had a hunch that this conversation would spark some...

More »

26 new drugs permitted for sale without trials in India

-PTI NEW DELHI: Notwithstanding strong warnings by the parliamentary standing committee on health, new drugs continue to be approved for marketing in the country without holding any clinical trials on Indian patients to test their safety and efficacy. Sources in the Health Ministry admit that as many as 26 new drug molecules have been approved since 2010 without testing them through drug trials on local populations. While eight new drug molecules of biologicals...

More »

Price control, IP Act & regulatory framework: Revisiting some imp issues about Indian pharma-Ramesh Adige

-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...

More »

Diabetes combo pills spark worry-GS Mudur

-The Telegraph The proliferation and sales of anti-diabetes combination pills that contain two drugs to control blood sugar has stirred concerns in medical circles that a large proportion of diabetes patients in India are not receiving ideal treatment. A study by Indian and British researchers has shown that such two-drug combo pills accounted for more than half of the sales of all oral anti-diabetes medications in India last year, although doctors say...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close